Navigation Links
AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
Date:3/24/2011

REDWOOD CITY, Calif., March 24, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute or breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2010.

Net loss for the fourth quarter of 2010 was $3.5 million, or $5.23 per common share, compared with a net loss of $3.7 million, or $6.05 per common share, for the fourth quarter of 2009. Net loss for the year ended December 31, 2010 was $14.3 million, or $21.84 per common share, compared to a net loss of $20.1 million, or $34.93 per common share, for the year ended December 31, 2009.

Research and development expenses for the twelve and three months ended December 31, 2010 totaled $8.2 million and $1.9 million, compared to $15.5 million and $2.3 million for the twelve and three months ended December 31, 2009. General and administrative expenses were $4.0 million and $1.0 million for the year and quarter ended December 31, 2010, compared to $3.5 million and $1.0 million for the year and quarter ended December 31, 2009.

As of December 31, 2010, AcelRx had cash, cash equivalents and short-term investments of $3.7 million, compared to $12.5 million as of December 31, 2009. On February 16, 2011, AcelRx closed its initial public offering of 8.0 million shares of common stock resulting in net proceeds to AcelRx of $35.6 million.  We intend to utilize these funds primarily for advancement of our lead program, our hospital-based, patient-controlled analgesia (PCA) product, the Sufentanil NanoTab PCA System (ARX-01).

"We are pleased with our progress towards initiating the Phase 3 program for ARX-01 in acute post-operative pain," said Richard King, President and Chief Executive Officer of AcelRx. "We anticipate
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
2. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
3. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
4. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
7. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
8. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
9. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
10. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Antigen Discovery Inc. (ADi), a privately held ... the receipt of a National Institutes of Health (NIH) ... Institute of Dental and Craniofacial Research (NIDCR). The one-year ... Protein Microarray Chip, which will contain every protein in ... in the development of safe and effective vaccines and ...
(Date:10/22/2014)... Oct. 22, 2014  Paper Pak Industries, a ... APLS ® Body Guard Bio, a disposable, ... of bacteria and virus while protecting service providers ... Bio features a rugged, external nylon shell, watertight ... a leak-proof inner chamber that contains contaminated and ...
(Date:10/22/2014)...  With a vision to ensure safety and ... Pharmaceutical and Biotech manufacturer selects and implements the ... to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... by the Xyntek and Antares solution is an ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... CHICAGO, Nov. 29, 2011  In a new study presented today ... America (RSNA), growth hormone replacement for six months was found ... "This is the first time that the effects of growth ... study,s lead author, Miriam A. Bredella, M.D., a radiologist at ...
... Nov. 29, 2011  Newly developed computer software combined with magnetic ... assess a woman,s potential for a difficult childbirth. Results of ... the annual meeting of the Radiological Society of North America ... and not much wider than a fetus,s head, a baby ...
Cached Medicine Technology:Growth Hormone Increases Bone Formation in Obese Women 2Virtual Childbirth Simulator Improves Safety of High-Risk Deliveries 2Virtual Childbirth Simulator Improves Safety of High-Risk Deliveries 3
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... October 22, 2014 Lintelus, Inc., an ... Vice President of Sales, will be speaking on the ... Technology Expo on October 28, at the Holiday Inn ... a booth as well as a Tech Demo at ... can create a more engaging event experience. , The ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... women undergoing in vitro fertilization (IVF) are only about half ... popular assisted reproduction technique, new research indicates, and the racial ... the study, about 31 percent of white patients became pregnant ... Analyzing more than 4,000 IVF cycles over two years ...
(Date:10/22/2014)... taken by Firestone officials at the company,s rubber ... spread of the disease there and could prove effective ... provides health services to about 80,000 employees, retirees, their ... Between Aug. 1 and Sept. 23, there were 71 ... That incidence rate of 0.09 percent was much lower ...
(Date:10/20/2014)... Florida (PRWEB) October 20, 2014 With ... former Gov. Charlie Crist made a brief fundraising stop ... Orlando on Thursday. , Fresh from a debate last ... to take the stage for the first seven minutes ... the former governor described the incident in one word: ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3
... women with breast cancer, who are otherwise in good ... with chemotherapy. Studies in the past have shown that ... cancer significantly improves survival for women in their 50s ... ages 70 and older. Thus researchers suggest that chemotherapy ...
... a sleep disorder where a person's breathing stops or becomes ... airway. This can result in a number of serious health ... more likely to have diabetes than those without the sleep ... say patients with type 2 diabetes who also suffer from ...
... disorder where there is a loss of normal bone density. A ... for 10 years can increase bone density in postmenopausal women. Drugs, ... ,The research began with a three-year study on women ... to receive the drug for the next two years. Then for ...
... who receive hormone therapy after treatment for prostate cancer ... numbers as quickly as they once did //, according ... such as verbal skills, naming, visual-motor skills, and skills ... by the treatment. ,Researchers attribute the declines seen ...
... Letter, testing of eyes may tell more about the condition ... condition of the heart, kidneys or conditions like diabetes or ... I. Loewenstein, a retina specialist at Harvard-affiliated Massachusetts Eye and ... of blood vessels inside the eye with the damage that ...
... team had invented a synthetic paste that will make dental treatment ... almost similar to natural tooth enamel, and can be applied on ... dental caries affects a tooth, the affected part is removed and ... times such a procedure may require removing a part of the ...
Cached Medicine News:
... 96 well thermocycler with ... Peltier technology for fastest available ... to 4C/sec with High Pressure ... PCR plates. Includes motorized ...
... Faster speeds, highest precision, more ... flexible concept: this is the definition of ... few years nucleic acid research has been ... capabilities required of PCR Systems. To ...
... The Techne TC412 is a high performance, high ... Features & Benefits include: Flexible block ... programming, 8 peltiers, PC networking. Includes a ... to 32 Techne cyclers can be connected and ...
... The Tetrad 2 thermal cycler incorporates ... Research Tetrad chassis. As before, the chassis ... power supply is internal, while a large, color ... yet, updated automatic lids -- Moto Alphas -- ...
Medicine Products: